Because most sporadic dMMR CRCs exhibit MLH1 promoter methylation and many also have BRAF mutations, MLH1 promoter methylation analysis can be used to discriminate sporadic tumors from Lynch syndrome in patients without BRAF mutations. The gene discussed is BRAF; the disease is Lynch syndrome.